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Abstract 
 
Kinetochore plays an important role in the precise segregation of chromosome during 
mitosis. Kinetochore-associated protein 2 (KNTC2) is a component of kinetochore 
sub-modules. It had been reported that the expression levels of KNTC2 are low in 
non-dividing normal cells and specifically upregulated in tumor tissues of various 
cancer patients. Some reports have indicated the relationship between KNTC2 and in 
vivo growth of tumor tissues. However, no anti-cancer drug had been developed 
targeting KNTC2. Therefore, I started this study to confirm the involvement of KNTC2 
with in vivo growth of tumor tissues and show the possibility of developing siRNA 
drugs for cancer therapy. 
In the first chapter, I selected highly potent siRNAs in vitro that were common 
for human KNTC2 and mouse Kntc2. Their IC50 values were less than 100 pM. These 
siRNAs were encapsulated into a lipid nanoparticle (LNP) for in vivo studies. KNTC2 
siRNA-LNPs were intravenously administerd to otrhotopic tumor model mice of 
hepatocellular carcinoma (HCC). The expression levels of human KNTC2 and mouse 
Kntc2 mRNAs in tumor tissues were significantly suppressed by KNTC2 siRNA-LNPs. 
KNTC2 siRNA-LNPs also increased the phosphorylation levels of histone H3 (HH3) at 
serine 10 in tumor tissues and suppressed the in vivo growth of HCC without inducing 
liver damages. These data demonstrated the tumor-selective in vivo growth inhibitory 
activities of KNTC2 siRNA-LNPs. 
In the second chapter, I expanded the application of KNTC2 siRNA-LNP to 
lung cancer patient-derived tumor xenografts (PDXs). It had been reported that drug 
sensitivities of PDXs were more similar to tumor tissues of cancer patients compared 
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with conventional cancer cell lines. I firstly established three-dimensional (3D) culture 
systems of lung cancer PDXs (LC-45 and LC-60) because PDXs could not be 
maintained in two-dimensional culture systems. KNTC2 siRNA-LNP showed 
anti-tumor activities in 3D-culture system of LC-60 that was resistant to an approved 
drug, erlotinib. KNTC2 siRNA-LNP also showed anti-tumor activities in subcutaneous 
tumor model mice of LC-60 and LC-45 that was resistant to erlotinib. These results 
indicated that KNTC2 siRNA could be widely applied to lung cancer patients. 
Taken together, I conclude that KNTC2 is a promissing target for patients with 
hepatocellular carcinoma and lung cancer. Phosphorylated HH3 at serine 10 was 
considered to be one of the pharmacodynamic markers for KNTC2 siRNA. These 
studies indicated a possibility of developing siRNA drugs for cancer therapy.  
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Abbreviations 
 
ALT  Alanine transaminase 
AST  Aspartate transaminase 
CDCA1  Cell division associated 1 
CDK1  Cyclin-dependent kinase 1 
cDNA  Complementary deoxyribonucleic acid 
CENP  Centromere protein 
DPPC  Dipalmitoylphosphatidylcholine 
dsRNA  Double-stranded RNA 
HCC  Hepatocellular carcinoma 
Hec1  Highly expressed in cancer protein 1 
HH3  Histone H3 
KD  Knockdown 
KNTC2  Kinetochore-Associated Protein 2 
KSP  kinesin spindle protein 
LNP  Lipid nanoparticle 
Luc  Luciferase 
mRNA  Messenger ribonucleic acid 
miRNA  MicroRNA 
Ndc80  Nuclear division cycle 80 
Nek2  NIMA-related kinase 2 
OMe  O-methyl 
PBS  Phosphate-buffered saline 
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PDX  Patient-derived tumor xenograft 
PEG  Polyethylene glycol 
PEI  Polyethylenimine 
PLK1  polo-like kinase 1 
pre-miRNA Precursor miRNA 
pri-miRNA Primary miRNA 
PS  Phosphorothioate 
qPCR  Quantitative PCR 
RISC  RNA-induced silencing complex 
RNAi  RNA interference 
shRNA  Short (or Small) hairpin RNA 
siRNA  Small interferering RNA 
SPC25  spindle pole body component 25 homolog 
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General Introduction 
 
Kinetochore-associated protein 2 
Precise segregation of chromosome during mitosis is essential to maintain the 
homeostasis of cells and organs. Missegregation of chromosome results in genome 
instability such as aneuploidy and leads to tumorigenesis1. In prometaphase, spindle 
microtubules extend from centrosome and bind to duplicated sister chromatids at the 
kinetochore region. The sister chromatids are aligned in the metaphase plate and 
segregated to the opposite poles during anaphase (Fig. 1). 
Kinetochore consists of inner and outer sub-modules (Fig. 2). The inner 
kinetochore normally forms on highly repetitive DNA sequences and assembles into a 
specialized form of chromatin that persists throughout the cell cycle. The outer 
kinetochore is a proteinaceous structure with many dynamic components that assembles 
and functions only during mitosis2. The kinetochore has two main 
microtubule-interacting sub-modules, nuclear division cycle 80 (Ndc80) and Dam1. The 
Dam1 complex is thought to form a full or partial ring around microtubules, while the 
Ndc80 complex reaches out from the kinetochore with finger-like projections to contact 
the microtubule. The Ndc80 complex increases in copy number during anaphase, while 
the Dam1 subunits remain at a constant number3. 
Kinetochore-associated protein 2 (KNTC2), also called highly expressed in 
cancer protein 1 (Hec1)4, is a component of Ndc80 complex1 (Fig. 2). Human KNTC2 
mRNA is upregulated in tumor tissues of various cancer patients such as colorectal 
cancer5, gastric cancer5,6, breast cancer7, non-small cell lung carcinoma8, pancreatic 
cancer9 and hepatocellular carcinoma10. In contrast, the expression level of mouse 
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KNTC2 protein was reported to be relatively low in normal liver where cells were not 
actively dividing4. Threfore KNTC2 was recognized as a potential target for cancer 
therapy11. Actually, some group had investigated the relationship between KNTC2 and 
tumor growth using retrovirus vector12 or small molecules. However there is no 
approved drug targeting KNTC2 probably because it is difficult to develop molecules 
that are highly effective and specific to KNTC2. Retrovirus vector is not suitable for 
clinical development because of safety concerns. In this situation, I started to search for 
small interfering RNAs that were highly effective and specific to KNTC2. 
 
Small interfering RNA 
RNA-mediated gene silencing is an evolutionarily conserved immune system in which 
intracellular double-stranded RNAs (dsRNAs) are processed into small RNAs that 
suppress gene expression with complementary sequences13. In 1998, A. Fire et al 
investigated the mechanism of RNA-mediated gene silencing and discovered that 
injection of dsRNAs into C. elegans resulted in specific silencing of endogenous genes, 
which was called RNA interference (RNAi)14. RNAi was also confirmed in mammalian 
cells by Tuschl et al. in 200115. A. Fire and C. Mello received the Nobel Prize in 
Physiology or Medicine 2006 for their discovery of RNAi. 
Endogenous RNAi is triggered by microRNAs (miRNAs), that are transcribed 
as long primary miRNAs (pri-miRNAs) and processed into precursor miRNAs 
(pre-miRNAs) by Drosha (Fig. 3). These pre-miRNAs are then exported to the 
cytoplasm by the Exportin-5 and cleaved into small RNA duplexes of approximately 22 
nucleotides by Dicer16. One strand of the mature miRNA is loaded into RNA-induced 
silencing complex (RISC) and cleaves homologous mRNAs. 
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Small interfering RNAs (siRNAs) are chemically syntesized dsRNAs (19-21 
nucleotides) with overhanging 3' ends15. SiRNAs can be exogenously introduced into 
cells and enter the endogenous RNAi pathway at Dicer stage. The high specificity and 
efficiency of siRNA enabled us to easily validate molecular targets for anti-cancer drugs. 
For example, siRNAs targeting cell division associated 1 (CDCA1) and kinetochore 
associated 2 (KNTC2) were used in vitro to evaluate their involvement in the growth of 
lung cancer cell lines8.  
Issues that makes the clinical application of siRNA difficult are the 
vulnerability of siRNA to nuclease and immunogenicity. Several types of chemical 
modification10, such as 2'-OMe, was examined to improve the stability of siRNAs or 
prevent immune-responses (Fig. 4). However, in vivo evaluation of KNTC2 siRNA had 
not been fully performed probably because there was no efficient in vivo delivery 
system for siRNA. Therefore I used a lipid nanoparticle (LNP) that was developed 
in-house for siRNA delivery. 
 
Lipid nanoparticle 
Several kinds of in vivo delivery systems, such as polyethylenimine (PEI)17 and 
ligand-conjugate18, have been developed for siRNA. Among them, LNPs (Fig. 5) were 
considered to be most promissing for cancer therapy19,20. Actually, siRNAs targeting the 
essential cell-cycle proteins polo-like kinase 1 (PLK1) and kinesin spindle protein 
(KSP) were validated in vivo using LNP21. These siRNAs showed knockdown activities 
and growth inhivitory activities in a orthotopic tumor model mice of hepatocellular 
carcinoma. Furthermore, first-in-human clinical trial was started in 2010 using LNP 
formulation of siRNAs targeting VEGF and KSP22. However, there was no report on 
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KNTC2 siRNA encapsulated into LNP. Therefore I started to use KNTC2 siRNA and 
LNP. 
 
Objective of my studies 
To confirm the involvement of KNTC2 in the growth of tumor tissues and show the 
possibility of developing KNTC2 siRNA drug for cancer therapy, I firstly selected 
highly potent KNTC2 siRNAs in vitro and encapsulated them into a LNP for in vivo 
studies. Anti-tumor activities of KNTC2 siRNA-LNP were investigated using orthotopic 
tumor model mice of hepatocellular carcinoma (chapter 1) and subcutaneous tumor 
model mice of lung cancer patient-derived tumor xenograft (chapter 2). 
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Figure 1 Segregation of sister chromatids during mitosis (modified from 
reference1). In metaphase (upper panel), spindle microtubules (green) extend from 
centrosome (red) and bind to duplicated sister chromatids (blue) at the kinetochore 
region (orange). These sister chromatids are aligned in the metaphase plate and 
precisely segregated to the opposite poles during anaphase (lower panel).  
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Figure 2 Structure of kinetochore (modified from reference2). The kinetochore is 
composed of several inner and outer plates (shown in yellow). Inner plate is a chromatin 
structure containing nucleosomes. Outer plate has attachment sites for the plus ends of 
microtubules (green). Dam1 complex (purple) and Ndc80 complex (red) are 
microtubule-interacting sub-modules. KNTC2 is a component of Ndc80 complex. 
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Figure 3 Endognous RNAi pathways and their use as tools for gene silencing 
(modified from reference16). Endogenous RNAi is triggered by pi-miRNAs that are 
processed into pre-miRNAs by Drosha (blue). Pre-miRNAs are exported to cytoplasm 
by Exportin-5 (gray) and cleaved into miRNA by Dicer (orange). One strand of mature 
miRNA is loaded into Ago (yellow) and forms RISC (green). Exogenous siRNAs 
(green) are loaded into Ago in the same way as miRNA. 
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Figure 4 Chemical modifications of siRNA (modified from reference10). Chemical 
structures of modified nucleosides are shown. Me (pink), Methyl; S (blue), 
phosphorothioate; F (brown), Fluorine. 
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Figure 5 Schematic illustration of LNP (modified from reference20). LNPs 
encapsulating siRNAs mainly consist of ionizable lipid (green), phospholipid (blue), 
PEG-lipid (pink) and cholesterol (orange). 
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Chapter 1 : Anti-tumor activity of KNTC2 siRNA-LNP in 
orthotopic tumor model mice of hepatocellular carcinoma 
 
  
15 
 
Abstract 
 
To clarify the involvement of KNTC2 in the growth of tumor tissues and develop 
siRNA drug for cancer therapy, I firstly selected highly potent KNTC2 siRNAs in vitro 
using human and mouse hepatocellular carcinoma cell lines. These siRNAs were 
encapsulated into a LNP for in vivo studies. Anti-tumor activities of KNTC2 
siRNA-LNP were investigated using orthotopic tumor model mice of hepatocellular 
carcinoma. Single intravenous administration of KNTC2 siRNA-LNP specifically 
suppressed the expression levels of both human KNTC2 mRNA and mouse Kntc2 
mRNA in tumor tissues. Phosphorylation levels of histone H3 (HH3) at serine 10 in 
tumor tissues were increased by KNTC2 siRNA-LNP. Repeated administration of 
KNTC2 siRNA-LNP (twice a week) specifically inhibited the growth of tumor tissues 
without increasing the plasma AST and ALT levels. Their growth inhibitory activities 
were consistent with knockdown activities. These data strongly indicated that KNTC2 is 
a promising target for the treatment of HCC and that phosphorylated HH3 at serine 10 is 
one of the pharmacodynamic markers for KNTC2. 
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Introduction 
 
Hepatocellular carcinoma (HCC) arises from a variety of disease states such as liver 
fibrosis23, liver cirrhosis24 and non-alcoholic fatty liver disease25. The risk factors of 
HCC are virus, alcohol, fungi, obesity and type II diabetes26. These factors lead to 
chronic inflammation, destruction and regeneration of hepatocytes or hepatic stellate 
cells resulting in genetic mutations and dysregulation of growth signals27,28. The 
etiology of HCC is so complicated that monotherapy is considered to be insufficient to 
cure all types of HCC. 
Therapeutic options for HCC are surgical resection29, liver transplantation30, 
transarterial chemoembolization31, radiotherapy32, immunotherapy33, interferon34, iron 
chelator (deferasirox35) and molecular targeted agents, such as multi-kinase inhibitors 
(regorafenib36, sorafenib37), anti-glypican-3 antibody (codrituzumab38), mTOR 
inhibitors (everolimus39) and anti-VEGF antibodies (bevacizumab40, ramucirumab41). 
Those therapies show some clinical benefits for several types of HCC patients but their 
therapeutic effects are limited. HCC is still the second42 or third43 cause of 
cancer-related death in the world. Therefore, new drugs with different mechanism of 
actions are desired for HCC patients to improve their survival rates. 
As described in the general introduction, kinetochore-associated protein 2 
(KNTC2) plays an important role in chromosome segregation during mitosis4. Its 
expression levels are specifically upregulated in tumor tissues of various cancer patients 
including HCC44. Small molecules targeting KNTC2 protein (TAI-1, TAI-95) inhibited 
the in vitro growth of several HCC cell lines without inhibiting the growth of normal 
cell lines44. TAI-1 and TAI-95 also demonstrated in vivo growth inhibitory activity in a 
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subcutaneous HCC model of Huh-7 cells. However, there is no follow-up report on the 
relationship between KNTC2 and in vivo growth of HCC. It is still unclear whether 
KNTC2 is widely involved in the growth of HCCs. In addition, their mechanism of 
actions are not yet fully understood in vivo. 
To further investigate the relationship between KNTC2 and in vivo growth of 
HCC and confirm its tumor-selectivity, I firstly selected highly efficient KNTC2 siRNA 
and encapsulated them into a lipid nanoparticle. Their knockdown efficiencies, 
pharmacodynamic marker, growth inhibitory activities and hepatotoxicities were 
evaluated in orthotopic HCC model mice of Hep3B-luc cells. 
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Materials and Methods 
 
Chemical modification of siRNAs 
All siRNAs used in this study were chemically modified with 2'-O-methyl 
ribonucleotide to prevent immune responses45. Their sequences were listed in Table 1. 
Luc#1 was originally designed for firefly luciferase gene15 and used as the negative 
control for in vitro studies. NC#1 was designed as a mismatch control of Luc#1 and 
used for in vivo studies. 
 
In vitro selection of KNTC2 siRNAs 
Hep3B (human hepatocellular carcinoma cell line) and Hepa-1c1c7 (mouse liver 
hepatoma cell line) were purchased from American Type Culture Collection (ATCC, 
Manassas, VA). These cells were seeded in 96-well plates (BD Biosciences, San Jose, 
CA), cultured overnight and transfected with KNTC2 siRNAs (56 fM to 10 nM) using 
DharmaFECT1 (Thermo Fisher Scientific, Waltham, MA). Twenty four hours after the 
transfection, total RNA was extracted from cells and reverse-transcribed using Cells to 
Ct kit (Thermo Fisher Scientific). Copy number of each mRNA was measured by 
quantitative PCR method using Real-Time PCR System (Thermo Fisher Scientific). 
Primers and probes were listed in Table 2. IC50 value of each KNTC2 siRNA was 
calculated using Prism 5.0 (GraphPad, La Jolla, CA). 
 
Encapsulation of siRNAs into lipid nanoparticles 
KNTC2 siRNAs were encapsulated into lipid nanoparticles using microfluidic devices, 
Asia modules (model no. 210, Syrris, Royston, UK). LNP was composed of  
19 
 
3-((5-(dimethylamino) pentanoyl)oxy) -2,2-bis (((3-pentyloctanoyl)oxy)methyl)propyl 
3-pentyloctanoate (WO2016021683), dipalmitoyl phosphatidylcholine (NOF 
Corporation, Tokyo, Japan), cholesterol (Avanti Polar Lipids, Inc., Alabaster, Alabama) 
and GS-020 (NOF Corporation) at the molar ratio of 60%, 10.6%, 28% and 1.4%, 
respectively. Particle size and polydispersity index (PdI) of LNPs were measured by 
dynamic light scattering using Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). 
The ratio of siRNA entrapment was calculated using Ribogreen (Thermo Fisher 
Scientific, Waltham, MA) and 2% Triton X-100 as described elsewhere46. Briefly, LNPs 
were dissolved in 1% Triton X-100 to release the siRNAs. The concentrations of siRNA 
prior to and following the dissolution were calculated by applying Ribogreen (final 
0.25%) and measuring the fluorescence of Ribogreen using a spectrofluorometer, 
Envision (Excitation, 485 nm and Emission, 535 nm) and Envision software (version 
1.13.3009.1409, PerkinElmer, Inc., Waltham, MA, USA). 
 
Establishment of Hep3B cells stably expressing firefly luciferase gene 
Human hepatocellular carcinoma cell line, Hep3B was purchased from ATCC and 
cultured in EMEM (Thermo Fisher Scientific) containing 2% L-Glutamine and 10% 
fetal bovine serum (ATCC). Fluc gene fragment originally encoded by pGL3-Control 
vector (Promega, Madison, WI) was inserted into pAcGFP1-N In-Fusion Ready vector 
(Clontech, Mountain View, CA) and introduced into Hep3B cells. Clone number Ef2 
stably expressing Fluc gene (Hep3B-luc) was isolated in a medium containing 400 
µg/ml geneticin (Thermo Fisher Scientific). 
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Orthotopic tumor model of hepatocellular carcinoma 
C.B-17/Icr-scid/scid (SCID) mice (female, 5 or 6 weeks old) were purchased from 
CLEA (Kanagawa, Japan) and acclimatized. Hep3B-luc cells (3×105 cells) were washed 
with HBSS and centrifuged. The cell pellet was mixed with approximately equal 
volume (3 µl) of Matrigel (BD, Franklin Lakes, NJ) using MICROMAN (Gilson, 
Middleton, WI). The cell suspension (6 µl) was inoculated into the liver (left lobe) of 
SCID mice under anesthesia. Tumor growth was assessed by measuring the 
luminescence from Hep3B-luc cells using IVIS Spectrum (PerkinElmer, Waltham, MA). 
All experiments were approved by the Institutional Animal Care and Use Committee in 
Takeda Pharmaceutical Company Limited (approval number AU-00020234). 
 
Evaluation of anti-tumor activity using in vivo imaging system 
Eleven days after the inoculation, SCID mice with Hep3B-luc cells were divided into 
groups by the values of luminescence and body weight (N=5). KNTC2 siRNA-LNP (1 
mg/kg) was intravenously administered twice a week during the test period. Tumor 
growth was monitored by IVIS Spectrum (PerkinElmer) until five days after the last 
administration. Values of the final measurement were statistically analyzed by Dunnett's 
test. Growth inhibitory rates (%) were calculated using the formula (1-Y/X)×100; X, 
tumor weight of control group; Y, tumor weight of test group. Photographs of dissected 
tumor tissues were taken after the final measurement. 
 
Measurement of the hepatotoxicity 
Just after the final measurement of anti-tumor activity, blood was collected from the tail 
vein of mice under anesthesia (N=5). Plasma AST and ALT levels were measured by 
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DRI-CHEM 3500 (FUJIFILM, Tokyo, Japan). 
 
Measurement of the in vivo knockdown activities by qPCR  
KNTC2 siRNA-LNP (1 mg/kg) was intravenously administered to HCC model mice 
eighteen or nineteen days after the transplantation (N=3). Two days after the single 
administration, tumor tissue and normal liver were separately dissected from mice. Total 
RNA was extracted using TRIzol reagent (Thermo Fisher Scientific) and 
reverse-transcribed using superscript VILO cDNA synthesis kit (Thermo Fisher 
Scientific). Copy number of each mRNA was measured as described above. Values were 
statistically analyzed by Dunnett's test. 
 
Immunohistochemistry 
Administration of KNTC2 siRNA-LNP was performed in the same manner as above 
mentioned (N=2). Two days after the single administration, tumor tissue and normal 
liver were dissected together from mice. These samples were fixed with 10% Formalin 
Neutral Buffer Solution (Wako) and paraffin embedded. Tissue sections (5 µm) were 
deparaffinized and autoclaved in Real Target Retrieval solution (Agilent, Santa Clara, 
CA) for immuno-stimulation. Primary and secondary antibodies were listed in Table 3. 
They were diluted in normal goat serum blocking solution (Vector Laboratories, 
Burlingame, CA). Tissue sections were mounted on slides using VECTASHIELD 
Mounting Medium with DAPI (Vector Laboratories). Images were acquired by 
NanoZoomer Digital slide scanner (Hamamatsu Photonics, Shizuoka, Japan). 
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Results 
 
In vitro screening of KNTC2 siRNAs 
To find highly potent KNTC2 siRNAs, I designed approximately 250 siRNAs and 
measured their in vitro KD activities against human KNTC2 mRNA in Hep3B-luc cells. 
The IC50 values of selected eleven siRNAs (#1 to #11) were between 3 pM to 58 pM 
(Table 4). Among the eleven siRNAs, four siRNAs (#1 to #4) showed relatively high 
KD activity against mouse Kntc2 mRNA in Hepa1c1c7 cells. Their IC50 values were 94 
pM, 50 pM, 19 pM and 62 pM (Table 4). 
 
In vivo knockdown activities of KNTC2 siRNAs-LNP 
Knockdown activities of KNTC2 siRNAs (#1 and #3) were evaluated in orthotopic 
HCC model mice of Hep3B-luc. Single intravenous administration of KNTC2 
siRNA-LNP (1 mg/kg) significantly suppressed the expression levels of human KNTC2 
mRNAs by 74% (KNTC2#1) or 78% (KNTC2#3), respectively. In contrast, NC#1-LNP 
(negative control) did not significantly suppress the expression level of human KNTC2 
mRNA (Fig. 6A). Mouse Kntc2 mRNAs were also suppressed by 52% or 75% at the 
same dosage (Fig. 6B). Lower dosage of KNTC2 siRNA-LNP (0.3 mg/kg) also 
suppressed the expression levels of human KNTC2 mRNAs by 55% or 68%, 
respectively (Fig. 6C). Mouse Kntc2 mRNAs were suppressed by 49% or 68% at the 
same dosage (Fig. 6D). 
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Pharmacodynamic marker of KNTC2 siRNAs-LNP. 
I next investigated a potential pharmacodynamic marker for KNTC2. Phosphorylation 
levels of histone H3 (HH3) at serine 10 in tumor tissues of HCC seemed to be increased 
by KNTC2 siRNAs-LNP (1 mg/kg) two days after the single intravenous administration 
(Fig. 7A, B and C). NC#1-LNP (negative control) did not seem to increase the 
phosphorylation levels of HH3 (Fig. 7D). In addition, phosphorylated HH3 seemed to 
be fragmented by KNTC2 siRNAs-LNP indicating that KNTC2 siRNA-LNP induced 
apoptosis (Fig. 7B, C). 
 
In vivo growth inhibitory activity of KNTC2 siRNAs-LNP 
Anti-tumor activities of KNTC2 siRNA-LNPs were evaluated at the same dosage as 
described above. Repeated administration (twice a week) of KNTC2 siRNA-LNP (1 
mg/kg) significantly inhibited the in vivo growth of Hep3B-luc cells as measured by 
IVIS (Fig. 8A, E) and tumor weight (Fig. 8B). NC#1-LNP (negative control) did not 
significantly inhibit the in vivo growth of Hep3B-luc cells. The growth inhibitory rates 
were 94% (KNTC2#1) or 99% (KNTC2#3) as calculated by tumor weight (Fig. 8B). 
These values were consistent with the appearance of tumor tissues (Fig. 8F). Body 
weights of mice were not significantly changed by the repeated administration of 
KNTC2 siRNA-LNP at the dosage of 1 mg/kg (Fig. 8G). Lower dosage of KNTC2 
siRNA (0.3 mg/kg) also significantly inhibited the in vivo growth of Hep3B-luc cells as 
measured by IVIS (Fig. 8C) and tumor weight (Fig. 8D). The growth inhibitory rates 
were 54% (KNTC2#1) or 87% (KNTC2#3) as calculated by tumor weight (Fig. 8D). 
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Hepatotoxicity of KNTC2 siRNA-LNPs in orthotopic HCC model mice 
In parallel with the anti-tumor activity, we evaluated the hepatotoxicity of KNTC2 
siRNA-LNP by measuring the plasma AST and ALT levels. These levels were increased 
in control groups (PBS and NC#1) probably because orthotopic tumor tissues damaged 
the surrounding hepatic cells (Fig. 9A, B). In contrast, repeated administration of 
KNTC2 siRNA-LNP (1 mg/kg, twice a week) significantly lowered the plasma AST and 
ALT levels indicating that they suppressed the tumor growth without inducing 
hepatotoxicity. 
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Discussion 
 
To confirm the relationship between KNTC2 and in vivo growth of HCC, I firstly 
selected highly potent siRNAs for human and mouse KNTC2. These siRNAs were 
encapsulated into a LNP and administered to orthotopic HCC model mice. Their KD 
efficiency, pharmacodynamic marker, growth inhibitory activity and hepatotoxicity 
were evaluated. 
Among the four siRNAs that showed relatively high KD efficiencies in vitro, I 
selected KNTC2#1 and KNTC2#3 for in vivo study because KNTC2#2, KNTC2#3 and 
KNTC2#4 were designed very closely within the gene structure of KNTC2. In contrast, 
KNTC2#1 was designed apart from KNTC2#3. Both of these separately-designed 
siRNAs inhibited the in vivo growth of orthotopically inoculated Hep3B-luc cells (Fig. 
8). Their growth inhibitory activities were consistent with their KD activities (Fig. 6). In 
addition, the specificities of these KD and growth inhibitory activities were confirmed 
by the inability of NC#1. These data strongly indicated that KNTC2 was involved in the 
in vivo growth of orthotopically inoculated Hep3B-luc cells. 
In vivo growth inhibitory activity of KNTC2#1 was lower than that of 
KNTC2#3 at the dosage of 0.3 mg/kg (Fig. 8C, D), which was consistent with their in 
vitro and in vivo KD activities (Table 4 and Fig. 6C, D). In vivo growth inhibitory 
activity might not be detected by other siRNAs whose in vitro KD activities were much 
lower than KNTC2#1. Generally, administration of high dose siRNA and lipid 
nanoparticle (LNP) faces a risk of unexpected adverse events, such as off-target effect47 
and toxicity of cationic lipids48. Therefore lowering the dosage of siRNA and LNP by 
selecting highly potent siRNAs in vitro was considered to be crucial to demonstrate in 
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vivo growth inhibitory activity without causing adverse events. 
KNTC2 siRNA-LNP increased the phosphorylation levels of HH3 at serine 10 
in the tumor tissues (Fig. 7). Phosphorylation of HH3 at serine 10 is reported to be 
correlated with chromosome condensation during mitosis and meiosis49. Previous report 
demonstrated that anti-KNTC2 antibody disturbed mitosis and induced a fragmentation 
of nuclei4. In my in vitro studies, KNTC2 siRNA induced misalignment of chromosome 
in Hep3B-luc cells and G2/M cell cycle arrest (Figs. 10-11). Taken together, it was 
estimated that KNTC2 siRNA-LNP disturbed the mitosis of Hep3B-luc cells in tumor 
tissues and induced G2/M cell cycle arrest resulting in the chromosome condensation 
and accumulation of phosphorylated HH3. 
Compared to subcutaneous HCC models50, orthotopic HCC models were 
considered to be more suitable for the simultaneous evaluation of anti-tumor activity 
and hepatotoxicity because tumor tissues were mixed with normal liver (Fig. 8F). I 
selected KNTC2 siRNAs that suppressed not only human KNTC2 mRNA but also 
mouse Kntc2 mRNA to simultaneously investigate the effect of KNTC2 siRNA on 
tumor tissue and normal liver (Table 4). Hepatotoxicity of KNTC2 siRNA-LNP was not 
detected at the therapeutic dosage (1 mg/kg) suggesting the safety of targeting KNTC2 
(Fig. 9). 
Repeated administration of KNTC2 siRNAs-LNP significantly lowered the 
plasma AST and ALT levels in the orthotopic HCC model mice of Hep3B-luc (Fig. 9). 
AST and ALT are released mainly from damaged hepatocytes51. Therefore, it was 
speculated that a portion of normal hepatocytes were damaged by the aggressive 
proliferation of tumor tissues and that tumor shrinkage by KNTC2 siRNAs-LNP led to 
the protection of normal hepatocytes and decrease of plasma AST and ALT levels (Figs. 
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8-9). 
In conclusion, I demonstrated the anti-tumor activities of KNTC2 siRNAs-LNP 
in an orthotopic HCC model of Hep3B-luc cells at the dosage of 0.3 and 1 mg/kg. I also 
clarified the increase and segmentation of phosphorylated histone H3 in tumor tissues 
treated with KNTC2 siRNAs-LNP. Hepatotoxicity was not detected at the therapeutic 
dosage (1 mg/kg). These data strongly indicated that KNTC2 is a promising target for 
the treatment of HCC and that phosphorylated HH3 at serine 10 is one of the 
pharmacodynamic markers for KNTC2. 
 
  
28 
 
Tables and Figures 
 
Table1 List of chemically modified siRNAs. Small cases "r", "d" and "s" indicate 
ribonucleotide, deoxy-ribonucleotide and phosphorothioate modification, respectively. 
Underline indicates 2'-O-methyl ribonucleotide. 
 
Luc siRNA (Luc#1) 
Sense 5'-r(CUUACGCUGAGUACUUCGA)-dTsdT-3' 
Antisense 5'-r(UCGAAGUACUCAGCGUAAG)-dTsdT-3' 
Negative control siRNA (NC#1) 
Sense 5'-r(CUUACCCUCAGUUGUUCGA)-dTsdT-3' 
Antisense 5'-r(UCGAACAACUGAGGGUAAG)-dTsdT-3' 
KNTC2 siRNA (KNTC2#1) 
Sense 5'-r(UGGAGGAUACUUUAGAACA)-dTsdT-3' 
Antisense 5'-r(UGUUCUAAAGUAUCCUCCA)-dTsdT-3' 
KNTC2 siRNA (KNTC2#2) 
Sense 5'-r(AUAGUCAACUUGGUAUAUU)-dTsdT-3' 
Antisense 5'-r(AAUAUACCAAGUUGACUAU)-dTsdT-3' 
KNTC2 siRNA (KNTC2#3) 
Sense 5'-r(UAGUCAACUUGGUAUAUUU)-dTsdT-3' 
Antisense 5'-r(AAAUAUACCAAGUUGACUA)-dTsdT-3' 
KNTC2 siRNA (KNTC2#4) 
Sense 5'-r(CAACUUGGUAUAUUUUCCA)-dTsdT-3' 
Antisense 5'-r(UGGAAAAUAUACCAAGUUG)-dTsdT-3' 
KNTC2 siRNA (KNTC2#5) 
Sense 5'-r(GUCUAGAGUCGUUGAGAAA)-dTsdT-3' 
Antisense 5'-r(UUUCUCAACGACUCUAGAC)-dTsdT-3' 
KNTC2 siRNA (KNTC2#6) 
Sense 5'-r(GACAUUGAGCGAAUAAAUC)-dTsdT-3' 
Antisense 5'-r(GAUUUAUUCGCUCAAUGUC)-dTsdT-3' 
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Table1 (continued) 
 
KNTC2 siRNA (KNTC2#7) 
Sense 5'-r(CUAGUUGUGCAAACCACGA)-dTsdT-3' 
Antisense 5'-r(UCGUGGUUUGCACAACUAG)-dTsdT-3' 
KNTC2 siRNA (KNTC2#8) 
Sense 5'-r(AUAUAUCCAUAGUGAAUAA)-dTsdT-3' 
Antisense 5'-r(UUAUUCACUAUGGAUAUAU)-dTsdT-3' 
KNTC2 siRNA (KNTC2#9) 
Sense 5'-r(GACAUUGAGCGAAUAAAUU)-dTsdT-3' 
Antisense 5'-r(AAUUUAUUCGCUCAAUGUC)-dTsdT-3' 
KNTC2 siRNA (KNTC2#10) 
Sense 5'-r(UAAACAAACCGACAUCUGA)-dTsdT-3' 
Antisense 5'-r(UCAGAUGUCGGUUUGUUUA)-dTsdT-3' 
KNTC2 siRNA (KNTC2#11) 
Sense 5'-r(CAGACAUUGAGCGAAUAAA)-dTsdT-3' 
Antisense 5'-r(UUUAUUCGCUCAAUGUCUG)-dTsdT-3' 
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Table 2 List of species specific qPCR primers and probes. Small case "d" indicates 
deoxy-ribonucleotide. 
 
Human KNTC2 Sequence 
Fw primer 5'-d(GAGGTACATAAACTTGAGCCCTGTATT)-3' 
Rev primer 5'-d(TGCTGAGAATTCCAAAGGTTATGA)-3' 
Probe 5'-d(TGGCACCAGCCTCGGGATTAAACTTAA)-3' 
Human ACTB Sequence 
Fw primer 5'-d(CCTGGCACCCAGCACAAT)-3' 
Rev primer 5'-d(GCCGATCCACACGGAGTACT)-3' 
Probe 5'-d(ATCAAGATCATTGCTCCTCCTGAGCGC)-3' 
Mouse Kntc2 Sequence 
Fw primer 5'-d(GAATAAAAAGAGGCATCTGGAGGATAC)-3' 
Rev primer 5'-d(CCTCCTTCAGCATCCTCACAGT)-3' 
Probe 5'-d(CAACTGAACACCATGAAAACGGAAAGCAA)-3' 
Mouse Actb Sequence 
Fw primer 5'-d(CACTATTGGCAACGAGCGG)-3' 
Rev primer 5'-d(TCCATACCCAAGAAGGAAGGC)-3' 
Probe 5'-d(TCCGATGCCCTGAGGCTCTTTTCC)-3' 
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Table 3 List of antibodies used in immunohistochemistry. 
 
Primary antibody Clone Host Maker Number Dilution 
Anti-phospho-Histone H3 
(Ser10) XP 
D2C8 rabbit Cell Signaling #3377 1/200 
Anti-alpha-Tubulin DM1A mouse Sigma T6199 1/200 
Secondary antibody Clone Host Maker Number Dilution 
Anti-rabbit IgG (H+L),  
Alexa Fluor 568 conjugate 
poly. goat ThermoFisher A11036 1/200 
Anti-mouse IgG (H+L),  
Alexa Fluor 488 conjugate 
poly. goat ThermoFisher A11001 1/200 
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Table 4 In vitro knockdown activity of KNTC2 siRNAs. Knockdown activities of 
KNTC2 siRNAs were evaluated using human and mouse hepatocelluar carcinoma cell 
lines, Hep3B-luc and Hepa-1c1c7. IC50 values of KNTC2 siRNAs were listed 
separately for human and mouse KNTC2. 
 
 
IC50 value (pM) 
siRNA Human (Hep3B-luc) Mouse (Hepa1c1c7) 
KNTC2#1 15  94  
KNTC2#2 14  50  
KNTC2#3 3  19  
KNTC2#4 20  62  
KNTC2#5 24  >10,000 
KNTC2#6 40  1,454  
KNTC2#7 58  >10,000 
KNTC2#8 22  >10,000 
KNTC2#9 16  455  
KNTC2#10 5  >10,000 
KNTC2#11 27  >10,000 
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Figure 6 Suppression of human KNTC2 and mouse Kntc2 mRNAs by KNTC2 
siRNAs in the tumor tissues of HCC model mice. KNTC2 siRNAs (#1 or #3) 
encapsulated into LNP were intravenously administered to orthotopic HCC model mice 
of Hep3B-luc cells at the dosage of 1 mg/kg (A, B) or 0.3 mg/kg (C, D). NC#1 was 
used as a negative control. Knockdown activities were evaluated two days after the 
single administration. (A, C) Human KNTC2/ACTB mRNA. (B, D) Mouse Kntc2/Actb 
mRNA. Values were represented by mean+SD. n.s., no significant difference; **, 
p<0.01; ***, p<0.001 by Dunnett's test (N=3). 
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Figure 7 Induction of phosphorylated histone H3 by KNTC2 siRNA in the tumor 
tissues of HCC model mice. KNTC2 siRNAs (#1 or #3) encapsulated into LNP were 
intravenously administered to orthotopic HCC model mice of Hep3B-luc cells at the 
dosage of 1 mg/kg (B, C). NC#1 was used as a negative control (D). Two days after the 
single administration, orthotopic tumor tissues were dissected to stain phosphorylated 
histone H3 (red) and alpha-tubulin (green). Scale bar = 50 µm 
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Figure 8 Anti-tumor activities of KNTC2 siRNA-LNPs in orthotopic tumor model 
mice of HCC. KNTC2 siRNAs (KNTC2#1 or KNTC2#3) encapsulated into LNP were 
repeatedly (twice a week) administered to orthotopic HCC model mice of Hep3B-luc 
cells at the dosage of 1 mg/kg (A, B, E, F and G) or 0.3 mg/kg (C, D). NC#1 was used 
as a negative control. Growth inhibitory activities were evaluated by IVIS (A, C, E) and 
tumor weight (B, D). Tumor tissues were dissected at the end of evaluation (F). Body 
weights of mice were measured twice a week (G). Values were represented by 
mean+SD. n.s., no significant difference; *, p<0.05; **, p<0.01; ***, p<0.001 by 
Dunnett's test (N=5). 
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Figure 9 Hepatotoxicities of KNTC2 siRNA-LNPs in orthotopic tumor model mice 
of HCC. KNTC2 siRNAs (KNTC2#1 or KNTC2#3) encapsulated into LNP were 
repeatedly (twice a week) administered to orthotopic HCC model mice of Hep3B-luc 
cells at the dosage of 1 mg/kg. NC#1 was used as a negative control. Plasma AST level 
(A) and ALT level (B) were measured four days after the fourth administration. Values 
were represented by mean+SD. n.s., no significant difference; *, p<0.05 by Dunnett's 
test (N=5) 
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Figure 10 Effect of KNTC2 siRNA on the chromosome alignment in a HCC cell 
line. Hep3B-luc cells (1×105 cells) were seeded in 6 well-plates and cultured overnight. 
These cells were transfected with KNTC2 siRNA (KNTC2#3) at the concentration of 10 
nM using DharmaFECT1 and fixed with formalin 24 hours after the transfection. Luc#1 
was used as a negative control. Tubulin (green), DAPI (blue) and KNTC2 (red) were 
stained and observed using fluorescence microscope. 
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Figure 11 Effect of KNTC2 siRNA on the cell cycles of HCC and normal cell lines. 
Hep3B-luc cells or WI-38 cells (1×105 cells) were seeded in 6 well-plates and cultured 
overnight. These cells were transfected with KNTC2 siRNA (KNTC2#3) at the 
concentration of 10 nM using DharmaFECT1. Luc#1 was used as a negative control. 
Cells were collected using trypsin and fixed with ethanol 24, 48 and 72 hours after the 
transfection. Nuclear DNAs were stained with propidium iodide and analyzed by Cell 
Lab Quanta MPL. 
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Chapter 2 : Anti-tumor activity of KNTC2 siRNA-LNP 
against lung cancer patient- derived tumor xenografts 
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Abstract 
 
Using the KNTC2 siRNA-LNP validated in chapter 1, I next evaluated its anti-tumor 
activities against lung cancer patient-derived tumor xenografts (PDXs) that had been 
reported to be more relavant to the tumor tissues of cancer patients compared with 
conventional cancer cell lines. In this chapter, I firstly established three-dimensional 
(3D) culture systems of lung cancer PDXs (LC-45 and LC-60) and confirmed their 
correlation with in vivo subcutaneous tumor models by checking their sensitivities to an 
approved drug, erlotinib. Knockdown and anti-tumor activities of KNTC2 siRNA-LNP 
were clarified in the 3D-culture system and subcutaneous tumor model of LC-60 that 
was resistant to erlotinib. KNTC2 siRNA-LNP also exhibited in vivo knockdown and 
antitumor activity against LC-45 that was sensitive to erlotinib. These results suggest 
that KNTC2 siRNA-LNP could be widely applied to lung cancer patients. 
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Introduction 
 
Tumor tissues are highly heterogeneous. Several types of cell interact with each other 
making it difficult to predict their drug sensitivities52. Reconstruction of this 
heterogeneity in a preclinical study may provide a method to predict the efficacy of 
novel anticancer drugs in clinical study53. Patient-derived tumor xenografts (PDXs) are 
established by maintaining the tumor tissues derived from patients with cancer in the 
flank of immuno-deficient mice54,55. Compared with conventional cancer cell lines, 
PDXs have been reported to be more relevant to the original tumor tissues of patients 
with cancer in terms of drug sensitivity, heterogeneity and genetic status56-60. 
Accordingly, PDXs may be used for the evaluation of new anticancer drugs61. 
Lung cancer is categorized into small cell lung cancer (SCLC) and non-small 
cell lung cancer (NSCLC). The most common types of NSCLC are squamous cell 
carcinoma, adenocarcinoma and large cell carcinoma62. These types of NSCLC are 
further classified into several stages according to their disease status63. Several 
anticancer drugs have been developed for each type of lung cancer. Their molecular 
targets include epidermal growth factor receptor (EGFR) tyrosine kinase (erlotinib64, 
gefitinib65 and afatinib66), rearranged anaplastic lymphoma kinase (crizotinib67, 
ceritinib68 and alectinib69), folate-dependent enzymes (pemetrexed70), vascular 
endothelial growth factor (bevacizumab71), C-X-C chemokine receptor type 4 
(LY251092472) and programmed cell death protein 1 (nivolumab73). Although these 
drugs demonstrated therapeutic effects on several types of lung cancer, other treatment 
options are desired to increase their combined effects. 
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In chapter 1, I clarified the tumor-selective in vivo growth inhibitory activities 
of KNTC2 siRNA-LNPs in orthotopic tumor model mice of HCC74. However, it 
remains unclear whether KNTC2 siRNA-LNPs exhibit anti-tumor activities against lung 
cancer PDXs. 
To expand the application of KNTC2 siRNA-LNP to lung cancer PDXs, I 
investigated its anti-tumor activities in three-dimensional culture system and 
subcutaneous tumor models of lung cancer PDXs, LC-45 (sensitive to erlotinib) and 
LC-60 (resistant to erlotinib). 
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Materials and Methods 
 
Lung cancer PDXs 
Lung cancer PDXs, LC-45 (adenocarcinoma) and LC-60 (small or large cell carcinoma) 
were purchased from the Central Institute for Experimental Animals (Kanagawa, Japan). 
PDXs were maintained in the flank of BALB/c nude mice (20-25 g; 7-8 weeks old; 
female; Charles River Laboratories International, Inc., Kanagawa, Japan). When PDXs 
grew to approximately 1,000 mm3, PDXs were excised and cryopreserved in small 
pieces (40-70 μm) using Cell Banker 2 (Nippon Zenyaku Kogyo, Co., Ltd., Fukushima, 
Japan). Humane endpoint was determined by 20% weight loss and the maximum tumor 
size was 1,000 mm3. Mice were maintained in specific pathogen-free conditions with 
free access to food and water, under a constant temperature of 22±2˚C and a 12/12 h 
light/dark cycle. All experiments were approved by the Institutional Animal Care and 
Use Committee in Takeda Pharmaceutical Company Limited (Fujisawa, Japan; approval 
number 11387). 
 
Chemical modification of siRNAs 
KNTC2 siRNA and Luc siRNA (negative control) 15 were synthesized by GeneDesign 
(Osaka, Japan) and chemically modified with 2'-O-methyl ribonucleotide to prevent 
immune responses, as described previously 45. Different from chapter 1, 
phosphorothioate (PS) modifications were not used for KNTC2 siRNA to prevent 
optical isomers. The sequences and chemical modifications are listed in Table 5.  
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Encapsulation of siRNAs into lipid nanoparticles 
KNTC2 siRNA and Luc siRNA were encapsulated into lipid nanoparticles in the same 
way as described in chapter 1. 
 
Evaluation of knockdown activities in subcutaneous tumor models of 
PDXs 
Small pieces (~100 mm3) of PDXs were inoculated in the flank of BALB/c nude mice 
using a trocar needle (KN-391; Natsume Seisakusho, Co., Ltd., Tokyo, Japan). Tumor 
sizes were measured with calipers and defined as (major axis) x (minor axis)2 / 2, as 
previously described. When the tumor sizes reached between 100 and 400 mm3, 9 mice 
were selected from a total of 20 mice and divided into three groups (PBS, KNTC2 and 
Luc) using EXSUS 2014 software (version8.0, CAC Exicare Corporation, Tokyo, 
Japan). KNTC2 siRNA encapsulated into LNP (KNTC2-LNP) was intravenously 
administered at 5 mg/kg (n=3). Luc siRNA-LNP was used as the negative control. PBS 
was administered to the vehicle control group. Knockdown activity was measured 3 
days after the single administration. Total RNA was extracted from tumor tissue using 
TRIzol® (Life Technologies; Thermo Fisher Scientific, Inc.) and reverse transcribed 
(thermocycling conditions: 25˚C for 10 min; 42˚C for 1 h; and 85˚C for 5 min) using 
SuperScript VILO cDNA Synthesis kit (Thermo Fisher Scientific, Inc.). The copy 
numbers of human KNTC2, human β-actin (ACTB), mouse Kntc2 and mouse Actb 
mRNA were individually measured by quantitative polymerase chain reaction (using a 
Real-Time PCR System (Thermo Fisher Scientific, Inc.). Species-specific qPCR 
primers and probes (Thermo Fisher Scientific, Inc.) are listed in Table 6. Copy numbers 
of KNTC2 or Kntc2 mRNA were individually normalized to ACTB or Actb mRNA. 
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Evaluation of growth inhibitory activities in subcutaneous tumor 
models of PDXs 
A total of 10 or 15 mice were selected from 20 or 45 mice (total number of mice, 65), 
respectively, and divided into two (control and erlotinib) or three (control, KNTC2 and 
Luc) groups using EXSUS 2014 software. Erlotinib (Carbosynth, Ltd., Compton, UK) 
was orally administered at 100 mg/kg once a day for 11 days (LC-45) or 5 days (LC-60) 
In addition, 0.5% methylcellulose was used as the control (n=5). KNTC2-LNP was 
intravenously administered at 5 mg/kg at three time points, with three days between 
each administration. Luc siRNA-LNP was used as the negative control. PBS was 
administered to the vehicle control group. Tumor sizes were measured as 
aforementioned. Growth inhibitory rate (%) was calculated using the formula: (1- tumor 
growth of treated group / tumor growth of untreated group) x100%. 
 
Cryopreservation of PDXs for 3D culture systems 
PDXs were excised from BALB/c nude mice and cut into small pieces (~100 mm3). 
These pieces were digested in Dulbecco’s modified eagle’s medium (DMEM) high 
glucose (Thermo Fisher Scientific, Inc.) containing 75 U/ml collagenase type XI (Sigma 
Aldrich; Merck KGaA, Darmstadt, Germany), 125 μg/ml dispase type II (Thermo 
Fisher Scientific, Inc.), 2.5% (v/v) fetal bovine serum (Thermo Fisher Scientific, Inc.) 
and 100 U/ml penicillin/streptomycin at 37˚C. Digestion was terminated prior to 
complete dispersion of the PDXs. PDXs of intermediate size (between 40 and 100 μm) 
were collected using a cell strainer and cryopreserved in a Cell Banker 2 (Nippon 
Zenyaku Kogyo, Co., Ltd.) at -160˚C. 
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3D-culture of cryopreserved PDXs 
Cryopreserved PDXs were suspended in Advanced DMEM/F12 (ratio, 1:1; Thermo 
Fisher Scientific, Inc.) containing 10 mM 4-(2-hydroxyethyl)-1- piperazine 
ethanesulfonic acid, 2 mM GlutaMAX-1 (Thermo Fisher Scientific, Inc.), N2 
supplement (Thermo Fisher Scientific, Inc.), B27 supplement (Thermo Fisher Scientific, 
Inc.), 100 U/ml penicillin/streptomycin, 1 mM N-acetylcysteine, 500 nM A-83-01 and 1 
μM SB202190 as previously described 75. Subsequently, PDXs were seeded in 
U-bottom 96-well plate (Sumitomo Bakelite Co., Ltd., Tokyo, Japan) and cultured in a 
5% CO2-humidified chamber at 37˚C. Growth of PDX was monitored using Cellavista 
and Cellavista Control and Evaluation Software version 2.1.0.876 (Synentec GmbH, 
Elmshorn, Germany). Data was omitted when the shape of PDX was not recognized by 
Cellavista. 
 
Evaluation of knockdown activities in 3D-culture system of PDXs 
PDXs were cultured for four days as aforementioned. KNTC2-LNP was added at 
concentrations of 10 nM, 100 nM and 1 μM (n=6). PDXs were subsequently cultured 
for an additional three days and mixed together due to each tumor volume being too 
small to obtain a sufficient amount of total RNA for evaluating knockdown activities. 
Total RNA was extracted using RNeasy kit (Qiagen GmbH, Hilden, Germany) and 
reverse-transcribed using SuperScript VILO cDNA Synthesis kit, according to 
manufacturer’s protocols. Knockdown activities were calculated as aforementioned.  
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Evaluation of growth inhibitory activities in a 3D-culture system of 
PDXs 
PDXs were cultured for three (LC-60) or four (LC-45) days as aforementioned (n=6). 
KNTC2-LNP was added at concentrations ranging from 10 nM, 100 nM and 1 μM. 
Erlotinib (Carbosynth) was added at concentrations of 10 nM, 100 nM, 1 μM and 10 
μM using a sample-dispensing machine (HP D300 Digital Dispenser, Tecan Japan Co., 
Ltd., Kawasaki, Japan). Growth inhibitory rate was calculated using the formula as 
aforementioned. 
 
Statistical analysis 
Data was statistically analyzed using EXSUS 2014 software. Significance among 
groups was analyzed using Bartlett's test followed by Dunnett's test (in vivo studies) or 
Williams' test (in vitro studies). P<0.05 was considered to indicate a statistically 
significant difference. 
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Results 
 
Sensitivities of lung cancer PDXs to erlotinib in vitro and in vivo 
To select different types of lung cancer PDXs for the evaluation of KNTC2-LNP, the 
sensitivities of several PDXs to erlotinib (an approved drug for patients with lung 
cancer) were investigated. Among those PDXs, LC-45 exhibited relatively high 
sensitivity to erlotinib in a subcutaneous tumor model (Fig. 12A). Repeated oral 
administration of erlotinib (100 mg/kg, once a day) significantly (P<0.001) inhibited the 
tumor growth of LC-45 by 86%. In contrast, the same dosage of erlotinib did not inhibit 
the tumor growth of LC-60 (Fig. 12B). 
Sensitivities of LC-45 and LC-60 to erlotinib were also investigated in 
3D-culture systems. Erlotinib significantly (P<0.001) inhibited the growth of LC-45 by 
81% at the concentration of 1 µM (Fig. 13A). The growth of LC-60 was not inhibited 
by erlotinib at the same concentration indicating that LC-60 was less sensitive to 
erlotinib compared with LC-45 (Fig. 13B). 
 
Encapsulation of siRNAs into LNP 
The particle sizes of KNTC2 siRNA-LNP and Luc siRNA-LNP were 75 and 73 nm, 
respectively. PdIs were 0.012 and 0.022. The entrapment efficiencies were 98.2 and 
97.6%, demonstrating that each siRNA was successfully encapsulated into LNP. 
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Knockdown and growth inhibitory activity of KNTC2-LNP in 
3D-culture system of LC-60 
The knockdown activities of KNTC2-LNP were 60% at 10 nM, 79% at 100 nM and 
88% at 1 µM in 3D-culture systems of LC-60 (Fig. 14A). The knockdown activities of 
Luc siRNA-LNP (negative control) were markedly decreased compared with 
KNTC2-LNP, indicating the specificity of KNTC2 siRNA (Fig. 14B). 
Tumor growth of LC-60 was significantly inhibited by KNTC2-LNP at 100 nM 
and 1 µM (P<0.001; Fig. 15A). The growth inhibition rates were 21 and 63%, 
respectively. Luc siRNA-LNP (negative control) did not significantly inhibit the growth 
of LC-60 at the same concentrations, indicating that growth inhibition was specifically 
caused by the suppression of human KNTC2 mRNA expression (Fig. 15B). 
 
Knockdown and growth inhibitory activities of KNTC2-LNP in 
subcutaneous tumor model mice of lung cancer PDXs 
Knockdown and growth inhibitory activities of KNTC2-LNP were further investigated 
in the subcutaneous tumor model of LC-60. Single intravenous administration of 
KNTC2-LNP (5 mg/kg) significantly suppressed the expression levels of human 
KNTC2 and mouse Kntc2 mRNA in LC-60 by 27% and 46%, respectively (P<0.01; 
Figs. 16A-B). Luc siRNA-LNP (negative control) did not exhibit knockdown activities 
at the same dosage. Repeated intravenous administration of KNTC2-LNP (5 mg/kg, 
twice a week) significantly inhibited the growth of LC-60 by 67% (P<0.001; Fig. 16C). 
Luc siRNA-LNP did not inhibit the growth of LC-60 indicating that the growth 
inhibition was specifically caused by the suppression of human KNTC2 and mouse 
Kntc2 mRNA expression levels. 
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Knockdown and growth inhibitory activities of KNTC2-LNP were also 
investigated using another lung cancer PDX, LC-45. Single intravenous administration 
of KNTC2-LNP (5 mg/kg) significantly suppressed the expression levels of human 
KNTC2 and mouse Kntc2 mRNA in LC-45 by 63 and 60%, respectively (P<0.001; Figs. 
17A-B). Repeated intravenous administration of KNTC2-LNP (5 mg/kg, twice a week) 
significantly inhibited the growth of LC-45 by 63% (P<0.01; Fig. 17C) suggesting that 
KNTC2-LNP exhibits antitumor activity against various types of lung cancer PDXs. 
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Discussion 
 
To expand the application of KNTC2 siRNA-LNP, I evaluated its anti-tumor activities 
in 3D-culture systems and subcutaneous tumor models of lung cancer PDXs, LC-45 and 
LC-60. 
Lung cancer PDXs implanted into the flank of immuno-deficient mice were 
estimated to be composed of lung cancer patient-derived human cells and host 
mouse-derived stromal cells76. Stromal cells have been reported to affect the 
proliferation of cancer cells in tumor tissues77. Therefore, in the present study, KNTC2 
siRNA that suppressed not only human KNTC2 mRNA but also mouse Kntc2 mRNA 
was selected in order to clarify the involvement of KNTC2 in human-derived cancer 
cells and mouse-derived stromal cells (Figs. 16-17). The knockdown activities of 
KNTC2 siRNA were sufficient to inhibit the in vivo growth of LC-60 and LC-45. 
Negative control Luc siRNA did not inhibit the growth of these PDXs, indicating that 
their growths were dependent on KNTC2. 
Notably, KNTC2 siRNA inhibited the growth of LC-60 that was resistant to an 
approved drug, erlotinib (Figs. 15-16). According to previous studies, KNTC2 siRNA 
was estimated to impair the chromosome segregation of LC-60 leading to cell cycle 
arrest and apoptosis78,79. This molecular mechanism is distinct from that of erlotinib, 
which inhibits the auto-phosphorylation of EGFR tyrosine kinase80. Inhibitors of EGFR 
tyrosine kinase were reported to be ineffective in patients with lung cancer with 
mutations in KRAS81 or EGFR82. LC-60 exhibited a mutated KRAS gene (G12V). 
Therefore, KNTC2 may be a therapeutic target for patients with lung cancer that is 
resistant to erlotinib. 
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Several types of 3D-culture systems have been developed for PDXs to increase 
the efficiency of drug screening83-85. Efficiency of evaluating KNTC2 siRNA was 
increased by establishing 3D-culture systems of LC-45 and LC-60. In the case of 
erlotinib, the results of 3D-culture systems were similar to that of subcutaneous tumor 
models (Figs. 12-13). These results were consistent with previous reports demonstrating 
the similarities of 3D-culture systems to subcutaneous tumor models using other lung 
cancer PDXs 86,87. 
The maximum knockdown activity of KNTC2-LNP in the 3D-culture system 
was sufficient to inhibit the growth of LC-60 and predict the result of in vivo study (Figs. 
14-16). In contrast, growth inhibitory activity of KNTC2-LNP was not detected in the 
3D-culture system of LC-45 (data not shown). The reason for these results was 
speculated to be that the maximum knockdown activity of KNTC2-LNP was 
insufficient to inhibit the growth of LC-45. Applicability of the 3D-culture system to the 
evaluation of KNTC2-LNP was considered to be different between PDXs. 
In conclusion, I established in vitro 3D-culture systems of lung cancer PDXs 
and confirmed their correlation with in vivo subcutaneous tumor model mice. 
Anti-tumor activities of KNTC2 siRNA-LNP were clarified in the 3D-culture system 
and subcutaneous tumor model of LC-60 that was resistant to erlotinib. KNTC2 
siRNA-LNP also inhibited the in vivo growth of LC-45 that was sensitive to erlotinib. 
These results indicated that KNTC2 siRNA-LNP could be widely applied to lung cancer 
patients. 
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Tables and Figures 
 
Table 5 List of chemically modified siRNAs for Luc and KNTC2.  
 
siRNA Strand Sequence 
Luc siRNA 
Sense 5'-r(CUUACGCUGAGUACUUCGA)-dTsdT-3' 
Antisense 5'-r(UCGAAGUACUCAGCGUAAG)-dTsdT-3' 
KNTC2 siRNA 
Sense 5'-r(UAGUCAACUUGGUAUAUUU)-dTdT-3' 
Antisense 5'-r(AAAUAUACCAAGUUGACUA)-dTdT-3' 
r, ribonucleotide; d, deoxy-ribonucleotide; s, phosphorothioate modification; underline, 
2'-O-methyl ribonucleotide. 
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Table 6 List of quantitative PCR primers and probes specific for human KNTC2 
and mouse Kntc2 mRNAs.  
 
Gene Sequence 
Human KNTC2 
 
  Forward primer 5'-d(GAGGTACATAAACTTGAGCCCTGTATT)-3' 
  Reverse primer 5'-d(TGCTGAGAATTCCAAAGGTTATGA)-3' 
  Probe 5'-d(TGGCACCAGCCTCGGGATTAAACTTAA)-3' 
Human ACTB 
 
  Forward primer 5'-d(CCTGGCACCCAGCACAAT)-3' 
  Reverse primer 5'-d(GCCGATCCACACGGAGTACT)-3' 
  Probe 5'-d(ATCAAGATCATTGCTCCTCCTGAGCGC)-3' 
Mouse Kntc2 
 
  Forward primer 5'-d(GAATAAAAAGAGGCATCTGGAGGATAC)-3' 
  Reverse primer 5'-d(CCTCCTTCAGCATCCTCACAGT)-3' 
  Probe 5'-d(CAACTGAACACCATGAAAACGGAAAGCAA)-3' 
Mouse Actb  
 
  Forward primer 5'-d(CACTATTGGCAACGAGCGG)-3' 
  Reverse primer 5'-d(TCCATACCCAAGAAGGAAGGC)-3' 
  Probe 5'-d(TCCGATGCCCTGAGGCTCTTTTCC)-3' 
d, deoxy-ribonucleotide; KNTC2, kinetochore-associated protein 2; ACTB, β-actin. 
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Figure 12 Sensitivities of lung cancer patient-derived tumor xenografts to erlotinib in 
subcutaneous tumor model mice. LC-45 (A) and LC-60 (B) were inoculated in the flank of 
BALB/c nude mice. Erlotinib (100 mg/kg) was orally administered once a day during the test 
periods. Control group mice were treated with 0.5% methylcellulose. Values are presented as the 
mean+SD (n=5). n.s., no significance; ***, P<0.001 by Dunnett's test.  
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Figure 13 Sensitivities of lung cancer patient-derived tumor xenografts to erlotinib in 
3D-culture systems. Growth inhibitory activities of erlotinib were evaluated in 3D-culture 
systems of (A) LC-45 and (B) LC-60. The concentrations of erlotinib were 10, 100 nM, 1 and 
10 µM. Values are presented as the mean+SEM (n=4). n.s., no significance; **, P<0.005; ***, 
P<0.0005 compared with control by Williams' test.  
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Figure 14 Knockdown activities of KNTC2-LNP in 3D-culture system of LC-60. The 
knockdown activity of KNTC2-LNP (10 nM - 1 µM) was evaluated in a 3D-culture system of 
LC-60 (A). Luc siRNA-LNP was used as a negative control (B). The expression levels of 
human KNTC2 mRNAs were measured three days after the addition of lipid nanoparticles 
(n=6). 
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Figure 15 Growth inhibitory activity of KNTC2-LNP in 3D-culture system of LC-60. 
Growth inhibitory activity of KNTC2-LNP (A) was evaluated in 3D-culture systems of LC-60. 
Luc siRNA-LNP (B) was used as a negative control. These siRNAs were evaluated at 10, 100 
nM and 1 µM. Values are presented as the mean+SEM (n=5 or 6). n.s., no significance; ***, 
P<0.0005 compared with control by Williams' test.  
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Figure 16 Knockdown and growth inhibitory activities of KNTC2-LNP in subcutaneous 
tumor model mice of LC-60. Knockdown activities of KNTC2-LNP (5 mg/kg) were evaluated 
three days following a single intravenous administration. PBS and Luc siRNA-LNP were used 
as controls. The expression levels of human KNTC2 mRNA (A) and mouse Kntc2 mRNA (B) 
were investigated. Values are presented as the mean+SD (n=3). (C) Growth inhibitory activities 
of KNTC2-LNP (5 mg/kg) were evaluated during repeated intravenous administration (twice a 
week). Values are presented as the mean+SD (n=5). n.s., no significance; **, P<0.01; ***, 
P<0.001 compared with PBS/control by Dunnett's test. 
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Figure 17 Knockdown and growth inhibitory activities of KNTC2-LNP in subcutaneous 
tumor model mice of LC-45. Knockdown activities of KNTC2-LNP (5 mg/kg) were evaluated 
three days following a single intravenous administration. PBS and Luc siRNA-LNP were used 
as controls. The expression levels of human KNTC2 mRNA (A) and mouse Kntc2 mRNA (B) 
were investigated. Values are presented as the mean+SD (n=3). (C) Growth inhibitory activities 
of KNTC2-LNP (5 mg/kg) were evaluated during repeated intravenous administration (twice a 
week). Values are presented as the mean+SD (n=5). n.s., no significance; **, P<0.01; ***, 
P<0.001 compared with PBS/control by Dunnett's test. 
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General Discussion 
 
To clarify the involvement of KNTC2 in the growth of tumor tisses and show the 
possibility of developing KNTC2 siRNA drug for cancer therapy, I firstly selected 
highly potent siRNAs targeting KNTC2 in vitro and encapsulated them into a LNP for 
in vivo studies. Anti-tumor activities of KNTC2 siRNA-LNPs were confirmed in 
orthotopic tumor model mice of HCC (chapter 1) and subcutaneous tumor model mice 
of lung cancer PDX (chapter 2). 
Tumor tissues of cancer patients are rich in diversity and highly heterogenous. 
It is generally difficult to predict efficacies of anti-cancer drugs and determine the 
optimal dosage for each type of cancer patient. Therefore it was important to confirm 
the anti-tumor activities of KNTC2 siRNAs in several types of tumor models (HCC and 
lung cancer PDXs). The administration dosages of KNTC2 siRNA required to show 
anti-tumor activities were different between HCC model (0.3 mg/kg) and PDX models 
(5 mg/kg) probably because the efficiencies of deliverying KNTC2 siRNAs were 
different between these models. The in vivo knockdown efficiencies of KNTC2 siRNA 
were lower in PDX models compared with HCC model (Figs. 6, 16-17). According to a 
third-party report on a phase I clinical trial of siRNA-LNP, it seemed to be difficult to 
predict their knockdown efficiencies in cancer patients22. Predictive biomarkers were 
desired to estimate the knockdown efficiencies for each tumor type. 3D-culture systems 
of PDX as mentioned in chapter 2 might be one of the solutions to predict the 
compatibility of each cancer patient and siRNA-LNP. 
Liver is the most accessible tissue for siRNA-LNP. The first approved siRNA 
drug was designed to target transthyretin gene in the liver of patients with hereditary 
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transthyretin amyloidosis88. Among a wide variety of cancer models, HCC model 
seemed to be most suitable for the evaluation of siRNA-LNP21. Therefore I firstly 
selected orthotopic tumor model mice of HCC to evaluate the tumor selectivity of 
KNTC2 siRNA (Chapter 1). Using siRNAs that are common in human KNTC2 and 
mouse Kntc2, I could simultaneously evaluate the anti-tumor activities and 
hepatotoxicity in tumor tissues of HCC mixed with normal hepatocytes. The results 
indicated that anti-tumor activities of KNTC2 siRNAs were tumor selective (Fig. 8-9). 
To expand the application of KNTC2 siRNA-LNP, I next confirmed its 
anti-tumor activity in lung cancer PDX models that were reported to be more relevant to 
cancer patients (Chapter 2). This was the first report on the relationship between 
KNTC2 and PDX although there had been some reports on KNTC2 and commercially 
available cancer cell lines. My study indicated that KNTC2 siRNA-LNP could be 
applied to lung cancer patients who are resistant to an approved drug, erlotinib (Figs. 12, 
16). It is important for cancer patient to be suggested as much options as posssible 
because the heterogeneity of tumor tissues makes it difficult to develop anti-cancer 
drugs that were widely effective.  
Other groups have developed small molecules targeting KNTC2 and 
demonstrated their in vivo anti-tumor activities. These small molecules, such as INH178, 
TAI-189, TAI-9544 and TH-3990, were designed to inhibit the interaction between 
KNTC2 and a mitotic kinase, NIMA-related kinase 2 (Nek2) because phosphorylation 
of Ser165 in KNTC2 by Nek2 is critical for the modulation of chromosome 
segregation91. Cytotoxicities of TAI-1 and TAI-95 were checked in vitro using normal 
human fibloblast cell line, WI-38. Furthermore, hepatotoxicity and renal toxicity of 
TAI-1 were checked in vivo using CB17 SCID mice. However, its therapeutic window 
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was not clear because the dosage regimen of TAI-1 was slightly different between tumor 
xenograft models and toxicological studies. Developments of TAI-1 and its derivatives 
are not progressing by unknown reason. It is generally difiicult to control the specificity 
of small molecules. In contrast, the specificity of siRNA is generally high when used in 
low doses. I could confirm the anti-tumor acitivities of KNTC2 siRNA at the dosage of 
5 mg/kg in PDX models (Figs. 16-17). It might be possible to show the superiority of 
siRNA over small molecules in terms of specificity at therapeutic dosages. 
The mechanism of action is different between KNTC2 siRNA and small 
molecules targeting KNTC2 protein. As mentioned above, small molecules intercept the 
protein-protein interaction between KNTC2 and Nek2. They do not decrease the 
expression level of KNTC2 protein. In contrast, KNTC2 siRNA degrades KNTC2 
mRNA and decreases KNTC2 protein. There must be some biological differences such 
as downstream signaling, compensation of decreased KNTC2 by other protein or 
acquisition of drug resistance. I clarified that the phosphorylation of histone H3 
(p-HH3) is a pharmacodynamic marker of KNTC2 siRNA (Fig. 7). There is no report 
that demonstrated p-HH3 by small molecules targeting KNTC2. This marker is desired 
to be validated in clinical trials.  
In addition to KNTC2, there are many other molecules that play important role 
in chromosome segregation (Fig. 2). Some of these molecules are candidate targets for 
cancer therapy. For examples, there is a report that demonstrated in vivo anti-tumor 
activity of NUF2 shRNA using lentiviral vector and human pancreatic cancer cell line92. 
Another report demonstrated in vitro anti-tumor activitiy of Spc25 shRNA using 
lentiviral vector and human prostate cancer cell line93. Small molecules have also been 
developed targeting aurora kinases, CDK1, PLK1, EG5 CENP-E and 26S proteasome 
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complex94. Some of them were effective in clinical trials but most of their effects were 
low when used in single agent probably because tumor tissues acquire resistance. 
Severe adverse events such as neuropathies were also concerned. Considering the 
situation, KNTC2 seemed to be an ideal drug target because its expression profile was 
highly specific to tumor tissues of cancer patients. In addition, KNTC2 siRNA could be 
used in combination with pre-existing drugs because their mechanism of actions are 
different from that of KNTC2 siRNA. 
In conclusion, I clarified the tumor-selective in vivo growth inhibitory activites 
of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma (Chapter 
1)74 and expanded its application to subcutanenous tumor model mice of lung cancer 
patient-derived tumor xenografts (Chapter 2)95. These results indicated that KNTC2 
siRNA could be applied to other types of tumor models. Using the experimental 
procesure established in this study, candidate target molecules other than KNTC2 would 
be efficiently evaluated just by exchanging the sequence of siRNA. Therefore this study 
indicated the possibility of siRNA drugs for many types of cancer patients and target 
molecules.  
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